TuHURA Biosciences (HURA) Non-Current Debt (2011 - 2025)

TuHURA Biosciences (HURA) posted quarterly Non-Current Debt of $592000.0 for Q4 2025, little changed quarter-over-quarter from $592000.0 in Q3 2025.

TuHURA Biosciences (HURA) Non-Current Debt (2011 - 2025) Analysis & Trends

TuHURA Biosciences' Non-Current Debt history runs 7 years deep, the most recent figure standing at $592000.0 for Q4 2025.

In Q4 2025, Non-Current Debt changed N/A year-over-year to $592000.0; the TTM figure through Dec 2025 stood at $592000.0 (changed N/A YoY), while the FY2025 annual figure was $592000.0, changed N/A from the prior year.
Non-Current Debt for Q4 2025 stood at $592000.0, roughly flat from $592000.0 in the prior quarter.
The five-year high for Non-Current Debt was $592000.0 in Q3 2025, with the low at $503000.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	360.97 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	8.96 Bn
10	TuHURA Biosciences	37.61 Mn	37.61 Mn	-	-

Download Data